ClinicalTrials.gg
Not yet recruitingNCT07765901Updated Aug 21, 2026

Comparison of Postoperative Sensitivity Following Bulk-Fill and Conventional Incremental Composite Restorations: This Study Will be Proceed at Tertiary Care Hospital of Peshawar

An interventional study of conventional incremental composite and bulk-fill composite in To Compare Post Operative Sensitivity, sponsored by Prime Foundation. Not yet recruiting. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Prime Foundation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

When a dentist fills a cavity, regular filling material shrinks as it hardens and cannot be penetrated deeply by the curing light, forcing dentists to painstakingly apply it in tiny 2 mm layers to prevent it from pulling away from the tooth walls and creating gaps for bacteria. To solve this, advanced "bulk-fill" composites were created; they are more see-through to let light reach the very bottom and contain flexible components that absorb their own shrinkage stress. This allows dentists to safely fill a deep 4 to 5 mm cavity all at once, saving significant time while still ensuring a tight, bacteria-proof seal.

02

Conditions studied

  • To Compare Post Operative Sensitivity
03

In context

Lead sponsor

Prime Foundation is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of patient should range from 18-40 years.
  • Teeth with class I carious lesion in maxillary and mandibular 1st and 2nd molar is included.
  • The depth of cavity should be 4mm (with no sensitivity)
  • Pulpal and periapical pathology should be absent confirmed through radiograph and clinical tests

Exclusion criteria

Exclusion Criteria:

  • The patient must not have any of the following Irreversible pulpitis Necrotic pulp Previous restoration in tooth Periodontically compromised tooth Painkiller history for past 1-2 days Not undergone crown cutting Bruxism or clenching habits Cracked tooth syndrome Pre-existing Occlusal trauma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    conventional incremental composite group

    Other: conventional incremental composite

  • Experimental
    Bulk fill composite group

    Other: bulk-fill composite

Interventions

  • Otherconventional incremental composite

    Postoperative sensitivity following conventional incremental composite will be measured on follow-up after 1 week which will be done using the SCASS(Schiff cold air sensitivity

  • Otherbulk-fill composite

    Postoperative sensitivity following bulk-fill composite will be measured on follow-up after 1 week which will be done using the SCASS(Schiff cold air sensitivity

06

What researchers measure

Primary outcomes

  1. postoperative sensitivity

    Time frame: 1 week after procedure

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07765901
Lead sponsor
Prime Foundation
Responsible party
Dr. Fareeha Naz (Principle investigator, Prime Foundation) — Principal investigator
First posted
Aug 14, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion